•  
  •  
 

Abstract

Acromegaly is a rare endocrine clinical syndrome characterized by long-term elevated production of growth hormone (GH) due to a pituitary adenoma tumor. The main problem of acromegaly patients (AC-PTs) is prolonged elevated GH concentration, which leads to increased insulin-like growth factor 1 (IGF-1) production, causing the characteristic tissue and bone overgrowth. The appearance of diabetes in AC-PTs was linked with the high risks of cardiovascular morbidity, indicating that individuals with both conditions face heightened health challenges. Acromegaly typically has a higher cancer incidence rather than the general population. Without early diagnosis and effective treatment, excess GH can have widespread systemic effects, often leading to significant morbidity and mortality due to its multi-systemic effects. Specifically, our study is based on 33 comprehensive analyses of various articles, as evidenced by the references contributing to understanding the association between acromegaly and mortality risks. Multiple factors in acromegaly may decrease the mortality risks, such as the lifelong observation of IGF-1 and GH levels; in contrast, regular screenings for associated conditions like cancer are essential for optimizing patient outcomes. Regular follow-up to evaluate treatment efficacy and manage complications is important for maintaining health and reducing risks linked with acromegaly. This systematic review aims to investigate the factors contributing to increased mortality in AC-PT, with a focus on cardiovascular complications, metabolic disturbances, malignancies, and the impact of delayed diagnosis. The best clinical approach to care for acromegaly should include various specialists in endocrinology, pulmonology, neurology, cardiology, and psychiatry to provide the best management of acromegaly due to the vast range of complications. Early diagnosis, controlling hormonal changes, and treatment of Acromegaly may improve life expectancy in these patients and help reduce mortality rates.

References

[1] Iglesias P. Acromegaly and cardiovascular disease: associated cardiovascular risk factors, cardiovascular prognosis, and therapeutic impact. J Clin Med 2025;14(6):1906.

[2] Shakir OY, Atta SE, Gharab K, Ghannawi LA, Rahmah AM. Assessing Serum Asprosin Levels among Iraqi individuals diagnosed with acromegaly. Experimed 2025;15(1):49e56.

[3] Maione L, Chanson P. Acromegaly. In: Maleki M, Alizadehasl A, Haghjoo M, editors. Pituitary adenomas: the european neuroendocrine association's young researcher committee overview. Cham (Switzerland): Springer; 2022. p. 127e71.

[4] Farhan LO, Abed BA, Salman IN. Insulin like growth factor binding protein 7 as a novel diagnostic marker in sera of Iraqi patients with acromegaly. Baghdad Sci J 2023;20:979. 3 (Suppl.).

[5] Rosendal C, Arlien-Søborg MC, Nielsen EH, Feltoft CL, Rasmussen ÅK, Andersen MS, et al. Musculoskeletal disease in acromegalyda population-based registry study. Eur J Endocrinol 2025;192(3):308e17.

[6] Giustina A, Barkan A, Beckers A, Biermasz N, Biller BM, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metabol 2020;105(4):e937e46.

[7] Malek FK, Abbas SAR, Abed BA. Evaluation of the activity of arginase and some biochemical parameters in sera of patients with acromegaly. Baghdad Sci J 2024;21(12):3709e15.

[8] Esposito D. Acromegaly-mortality, morbidity and treatment patterns. 2022.

[9] Peixe C, Sanchez-García M, Grossman AB, Korbonits M, Marques P. Biochemical discrepancies in the evaluation of the somatotroph axis: Elevated GH or IGF-1 levels do not always diagnose acromegaly. Growth Hormone IGF Res 2022;64:101467.

[10] Carosi G, Mangone A, Sala E, Del Sindaco G, Mungari R, Cremaschi A, et al. Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study. Eur J Endocrinol 2021;185(2):289e97.

[11] Hameed AS, Abed BA, Mahdi OA, Rahmah AM. Assessment of malondialdehyde and soluble a-klotho serum levels in Iraqi acromegaly patients. Iraqi J Sci 2024;65(6):3008e14.

[12] Falch CM, Olarescu NC, Bollerslev J, Dekkers OM, Heck A. Trends in incidence and mortality risk for acromegaly in Norway: a cohort study. Endocrine 2023;80(1):152e9.

[13] Malek FK, Abbas SA-R, Abed BA. Measurement of arginase activity in Sera of Iraqi acromegaly patients with diabetes. Al-Mustansiriyah J Sci 2024;35(1):44e9.

[14] Danilowicz K, Sosa S. Acromegaly and cancer: an update. Arch Med Res 2023;54(8):102914.

[15] Melmed S. Acromegaly [published erratum appears in N Engl J Med 2007 Feb 22; 356 (8): 879]. N Engl J Med 2006; 355(24):2558e73.

[16] Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, et al. Long-term Survival and Costeffectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. JAMA Network Open. 2019;2(2):e190035-e.

[17] Atta SE, Hadi MA, Shakir OY, Gharab K, Salman IN. Evaluation of asprosin levels in growth hormonedeficient children. J Krishna Inst Med Sci Univ 2024;13(4): 65e73.

. [18] Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord 2008;9(1):33e9.

[19] Alhawyan FS. Mortality in acromegalic patients: etiology, trends, and risk factors. Cureus 2021;13(4):e14265.

[20] Giustina A, di Filippo L, Uygur MM, Frara S. Modern approach to resistant acromegaly. Endocrine 2023;80(2): 303e7.

[21] Vila G, Jørgensen JOL, Luger A, Stalla GK. Insulin resistance in patients with acromegaly. Front Endocrinol 2019;10:509.

[22] #039 Neill C, Gangat M, Radovick S. Growth hormone deficiency. Endocrines 2022;3(4):736e44.

[23] Hong S, Han K, Park CY. Long-term prognosis and systemic impact of acromegaly: analyses utilizing Korean National Health Insurance Data. Endocrinol Metab (Seoul) 2025;40(1): 1e9.

[24] Freda PU. Acromegaly: diagnostic challenges and individualized treatment. Expet Rev Endocrinol Metabol 2025:1e23.

[25] Galoiu S, Toma I-D, T anasie DI, B arbulescu A, Baciu I, Niculescu DA, et al. High mortality risk among women with acromegaly still persists. Front Endocrinol 2024;15.

[26] Cheng Y, Li W, Gui R, Wang C, Song J, Wang Z, et al. Dual characters of GH-IGF1 signaling pathways in radiotherapy and post-radiotherapy repair of cancers. Front Cell Dev Biol 2021;9:671247.

[27] Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acr

[28] Hong S, Kim K-S, Han K, Park C-Y. Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 2022; 43(15):1491e9.

[29] Colao A, Vandeva S, Pivonello R, Grasso LFS, Nachev E, Auriemma RS, et al. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). Eur J Endocrinol 2014;171(2):263e73.

[30] Bolfi F, Neves A, Boguszewski C, Nunes-Nogueira V. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 2018;179(1): 59e71.

[31] Esposito D, Olsson DS, Franzen S, Miftaraj M, N åtman J, Gudbjornsdottir S, et al. Effect of diabetes on morbidity and € mortality in patients with acromegaly. J Clin Endocrinol Metabol 2022;107(9):2483e92.

[32] Parolin M, Dassie F, Alessio L, Wennberg A, Rossato M, Vettor R, et al. Obstructive sleep apnea in acromegaly and the effect of treatment: a systematic review and metaanalysis. J Clin Endocrinol Metabol 2020;105(3):e23e31

. [33] Ghaemmaghami Z. Endocrine disorders and the cardiovascular system. In: Maleki M, Alizadehasl A, Haghjoo M, editors. Practical Cardiology: Principles and Approaches. 2nd ed. Philadelphia, PA: Elsevier; 2022. p. 685e91.

[34] Melmed S. Acromegaly pathogenesis and treatment. J Clin Investig 2009;119(11):3189e202.

[35] Yamamoto M, Takahashi Y. Genetic and epigenetic pathogenesis of acromegaly. Cancers 2022;14(16):3861. MA'AEN JOURNAL FOR MEDICAL SCIENCES 2025;4:89e99 97

[36] Crisafulli S, Luxi N, Sultana J, Fontana A, Spagnolo F, Giuffrida G, et al. Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol 2021; 185(2):251e63.

[37] Ogedegbe OJ, Cheema AY, Khan MA, Junaid SZS, Erebo JK, Ayirebi-Acquah E, et al. A comprehensive review of four clinical practice guidelines of acromegaly. Cureus 2022;14(9).

[38] Mikhailidis DP, GH S, PL A. Growth hormone, atherosclerosis and peripheral arterial disease: exploring the spectrum from acromegaly to growth hormone deficiency. Curr Vasc Pharmacol 2024;22(1):28e35.

[39] Wolters TL, Netea MG, Riksen NP, Hermus AR, NeteaMaier RT. Acromegaly, inflammation and cardiovascular disease: a review. Rev Endocr Metab Disord 2020;21(4):547e68.

[40] Macvanin M, Gluvic Z, Radovanovic J, Essack M, Gao X, Isenovic ER. New insights on the cardiovascular effects of IGF-1. Front Endocrinol 2023;14:1142644.

[41] Gadelha MR, Kasuki L, Lim DS, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 2019;40(1): 268e332.

[42] Laszczak K, Moqbil S, Niedobylski S, Warchoł K. Cardiovascular comorbidities in acromegaly. J Edu Health Sport 2021;11(8):283e90.

[43] Yang H, Tan H, Huang H, Li J. Advances in research on the cardiovascular complications of acromegaly. Front Oncol 2021;11:640999.

[44] Wolters TL, Roerink SH, Drenthen LC, van HarenWillems JH, Wagenmakers MA, Smit JW, et al. The course of obstructive sleep apnea syndrome in patients with acromegaly during treatment. J Clin Endocrinol Metabol 2020; 105(1):290e304.

[45] Langlois F, Suarez GM, Fleseriu M. Updates in rare and notso-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly. F1000Research 2020; 9:791. https://doi.org/10.12688/f1000research.22683.1. London (UK): F1000 Research Ltd.

[46] Orme S, McNally R, James PW, Davis J, Ayuk J, Higham C, et al. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levelsdA retrospective analysis from the UK Acromegaly Register 1970e2016. Clin Endocrinol 2024;100(6):558e64.

[47] Al-Beltagi M, Bediwy AS, Saeed NK. Insulin-resistance in paediatric age: Its magnitude and implications. World J Diabetes 2022;13(4):282.

[48] Lefta NA, Abed AY, Abed B A. Estimation of asprosin levels in female iraqi patients with type 2 diabetes and hypothyroidism. J Med Chem Sci 2023;6(2):433e9.

[49] Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis. J Clin Med 2021; 10(11):2419.

[50] De Fano M, Falorni A, Malara M, Porcellati F, Fanelli CG. Management of diabetes mellitus in acromegaly and cushing’s disease with focus on pasireotide therapy: a narrative review. Diabet Metabol Synd Obes 2024:2761e74.

[51] Arosio M, Sciannameo V, Contarino A, Berchialla P, Puglisi S, Pesatori A, et al. Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy. J Endocrinol Investig 2024;47(6): 1457e65.

[52] Hofbauer LC, Busse B, Eastell R, Ferrari S, Frost M, Müller R, et al. Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes Endocrinol 2022;10(3): 207e20.

[53] Salman IN, Mohammed NUG, Atta SE, Abed BA, Salim R. Serum visfatin in patients with type 2 diabetes mellitus and diabetic retinopathy. Diabetes Mellitus 2024;27(5):480e6.

[54] Kraemer WJ, Ratamess NA, Hymer WC, Nindl BC, Fragala MS. Growth hormone (s), testosterone, insulin-like growth factors, and cortisol: roles and integration for cellular development and growth with exercise. Front Endocrinol 2020;11:33.

[55] Haffner D, Grund A, Leifheit-Nestler M. Renal effects of growth hormone in health and in kidney disease. Pediatr Nephrol 2021;36(8):2511e30.

[56] Mihai G, Korbonits M. Hypertension in growth hormone excess and deficiency. In: Pappachan JM, Fernandez CJ, editors. Endocrine hypertension: from basic science to clinical practice. 1st ed. London (UK): Academic Press, an imprint of Elsevier; 2022. p. 217e47.

[57] Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 2022;10(11):804e26.

[58] Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study. J Clin Endocrinol Metabol 2021;106(12):3487e96.

[59] Kasuki L, Rocha PdS, Lamback EB, Gadelha MR. Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metabol 2019;63(6):630e7.

[60] Bolfi F, Neves A, Boguszewski C, Nunes-Nogueira V. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J EndocrinolArchives Endocrinol Metabol 2019;181(5):L5e6.

[61] Wu J-C, Huang W-C, Chang H-K, Ko C-C, Lirng J-F, Chen Y-C. Natural history of acromegaly: incidences, reoperations, cancers, and mortality rates in a national cohort. Neuroendocrinology 2020;110(11e12):977e87.

62] Lai NB, Garg D, Heaney AP, Bergsneider M, Leung AM. No benefit of dedicated thyroid nodule screening in patients with acromegaly. Endocr Pract 2020;26(1):16e21.

[63] Xiao Z, Xiao P, Wang Y, Fang C, Li Y. Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review. PLoS One 2023;18(11):e0285335.

[64] Demarchis L, Chiloiro S, Giampietro A, De Marinis L, Bianchi A, Fleseriu M, et al. Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries. Rev Endocr Metab Disord 2025:1e14.

[65] Stormann S, Cuny T. The socioeconomic burden of acro- € megaly. Eur J Endocrinol 2023;189(2):R1e10.

[66] Kyriakakis N. Exploring the morbidity and mortality in acromegaly. MD thesis. Leeds (UK): University of Leeds; 2021.

[67] Ahmad M, Weil RJ. Acromegaly: overview and current management options. The pituitary gland-an overview of pathophysiology and current management techniques. 2023.

[68] Ershadinia N, Tritos NA, Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc 2022;97(2):333e46. Rochester (MN): Elsevier.

[69] Clemmons DR, Bidlingmaier M. Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. Front Endocrinol 2023;14:1266339.

[70] Ghannawi L, Gharab K, Hadi M, Shakir O, Rahmah A. Spexin level in growth hormone deficiency Iraqi children. Ukrainian Biochem J 2024;96:55e61.

[71] Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, € V€alimaki MJ, L € oyttyniemi E, et al. Quality of life in treated € patients with acromegaly. J Clin Endocrinol Metabol 2006; 91(10):3891e6.

[72] Qiao N, He M, Shen M, Zhang Q, Zhang Z, Shou X, et al. Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies. Endocr Pract 2020;26(4):454e62.

[73] Stormann S, Schilbach K. Promising therapies for the treat- € ment of acromegaly. Expet Opin Pharmacother 2025 (justaccepted).

[74] Malenica M, Trbojevic T, Herceg S, Kukuruzovic M, Separovi c I, Rotim N, et al. Gigantism and Acromegaly through History. Acta Clin Croat 2024;63(2):384.

[75] Golounina O, Minniakhmetov I, Salakhov R, Khusainova R, Zakharova E, Bychkov I, et al. Pathogenetic therapeutic approaches for endocrine diseases based on antisense 98 MA'AEN JOURNAL FOR MEDICAL SCIENCES 2025;4:89e99 oligonucleotides and RNA-interference. Front Endocrinol 2025;16:1525373.

[76] Coopmans EC, Andela CD, Claessen KM, Biermasz NR. Evaluating the impact of acromegaly on quality of life. Endocrinol Metab Clin N Am 2022;51(4):709e25.

[77] Berkmann S, Brun J, Schuetz P, Christ E, Mariani L, Mueller B. Prevalence and outcome of comorbidities associated with acromegaly. Acta Neurochir 2021;163:3171e80.

[78] Colao A, Grasso L, Di Cera M, Thompson-Leduc P, Cheng W, Cheung H, et al. Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study. J Endocrinol Investig 2020;43:529e38.

[79] Stiles CE, Hossain B, Drake WM. Acromegaly. Medicine 2021;49(8):488e91.

[80] Mestron A, Webb SM, Astorga R, Benito P, Catal a M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151(4):439e46.

[81] Dal J, Skov BG, Andersen M, Feldt-Rasmussen U, Feltoft CL, Karmisholt J, et al. Sex differences in acromegaly at diagnosis: a nationwide cohort study and meta-analysis of the literature. Clin Endocrinol 2021;94(4):625e35.

[82] Lenders NF, McCormack AI, Ho KK. Management of endocrine disease: does gender matter in the management of acromegaly? Eur J Endocrinol 2020;182(5):R67e82.

[83] Parkinson C, Ryder WDJ, Trainer PJ, Group SAS. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metabol 2001;86(11): 5240e4.

[84] Tritos NA. Diagnosis of acromegaly. In: Blevins Jr LS, Aghi MK, editors. Acromegaly: a guide to diagnosis and treatment. Cham (Switzerland): Springer; 2022. p. 31e41.

[85] Cao R, Zhang D, Xing H, Wang M, Lu Z, Fan B. Acromegaly with joint pain as an initial symptom: A case report. Int J Rheum Dis 2023;26(6):1129e33.

86] Paragliola RM, Carrozza C, Corsello SM, Salvatori R. The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions. Expet Rev Endocrinol Metabol 2022;17(3):205e24.

[87] Hong S, Kim K-S, Han K, Park C-Y. Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J 2021; 43(15):1491e9.

[88] Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson DS. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 2018;178(5):459e69.

[89] Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol 2018; 179(1):59e71.

[90] Galoiu S, Toma I-D, T anasie DI, B arbulescu A, Baciu I, Niculescu DA, et al. High mortality risk among women with acromegaly still persists. Front Endocrinol 2024;15. 2024.

[91] Ritvonen E, Loyttyniemi E, Jaatinen P, Ebeling T, € Moilanen L, Nuutila P, et al. Mortality in acromegaly: a 20- year follow-up study. Endocr Relat Cancer 2016;23(6):469e80.

[92] Tritos NA, Mattsson AF, Vila G, Biller BMK, Klibanski A, Valluri S, et al. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol 2020;182(3):285e92.

[93] Arosio M, Sciannameo V, Contarino A, Berchialla P, Puglisi S, Pesatori AC, et al. Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy. J Endocrinol Investig 2024;47(6): 1457e65.

[94] Orme S, McNally R, James PW, Davis J, Ayuk J, Higham C, et al. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK Acromegaly Register 1970-2016. Clin Endocrinol (Oxf) 2024;100(6): 558e64.

[95] Biagetti B, Iglesias P, Villar-Taibo R, Moure M-D, Paja M, Araujo-Castro M, et al. Mortality in acromegaly diagnosed in older individuals in Spain is higher in women compared to the general spanish population. J Clin Endocrinol Metabol 2023;108(9):2193e202

Download

Share

COinS